Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 May 2;23(1):150.
doi: 10.1186/s13054-019-2449-y.

The global challenge of Candida auris in the intensive care unit

Andrea Cortegiani  1 , Giovanni Misseri  2 , Antonino Giarratano  2 , Matteo Bassetti  3 , David Eyre  4
Affiliations
Editorial

The global challenge of Candida auris in the intensive care unit

Andrea Cortegiani et al. Crit Care. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

AC is a member of the Advisory Board of Critical Care. GM and DE declare to have no competing interests. AG received grants, fees for educational presentation, and advisory board membership, without any relationship to the submitted work, from Pfizer, Merck Sharp, and Gilead. Outside the submitted work, MB has received funding for scientific advisory boards, travel and speaker honoraria from Angelini, AstraZeneca, Bayer, Biomerieux, Cidara, Cubist, Gilead, Pfizer, Melinta Therapeutics, Menarini, MSD, Nabriva, Paratek, Roche, Shionogi, Tetraphase, The Medicines Company and Astellas Pharma Inc.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Major issues related to Candida auris. Major issues related to Candida auris described with A.U.R.I.S. outline. MDR, multidrug resistant; ICU, intensive care unit
See this image and copyright information in PMC

References

    1. Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care. 2018;6:69. doi: 10.1186/s40560-018-0342-4. - DOI - PMC - PubMed
    1. Osei Sekyere J. Candida auris: a systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. MicrobiologyOpen. 2018;7:e00578. doi: 10.1002/mbo3.578. - DOI - PMC - PubMed
    1. Ruiz-Gaitan A, Moret AM, Tasias-Pitarch M, Aleixandre-Lopez AI, Martinez-Morel H, Calabuig E, et al. An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses. 2018;61:498–505. doi: 10.1111/myc.12781. - DOI - PubMed
    1. Cortegiani Andrea, Misseri Giovanni, Chowdhary Anuradha. What’s new on emerging resistant Candida species. Intensive Care Medicine. 2018;45(4):512–515. doi: 10.1007/s00134-018-5363-x. - DOI - PubMed
    1. Rhodes J, Abdolrasouli A, Farrer RA, Cuomo CA, Aanensen DM, Armstrong-James D, et al. Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris. Emerg Microbes Infect. 2018;7:43. - PMC - PubMed

Publication types

MeSH terms